Skip to main content

Advertisement

Table 2 Significance levels (P-values) for testing interaction with WHI trial interventions for SNPs in the MRPS30 region

From: Genetic variants in the MRPS30 region and postmenopausal breast cancer risk

Rs numbera Chromosome Position Minor/major allele MAFb ORc p.maind E-alonee E+Pf DMQg CaDh
7705343 5p12 44915334 G/A 0.40 1.18 0.000355 0.043 0.863 0.042 0.046
13159598 5p12 44841683 G/A 0.41 1.17 0.000425 0.056 0.920 0.057 0.048
11746980 5p12 44813635 A/G 0.41 1.16 0.000511 0.064 0.790 0.043 0.095
9790879 5p12 44935642 C/T 0.41 1.17 0.000963 0.117 0.762 0.042 0.047
2330572 5p12 44776746 C/A 0.42 1.16 0.00129 0.042 0.880 0.043 0.106
4415084 5p12 44698272 T/C 0.41 1.17 0.000436 0.242 0.944 0.127 0.146
994793 5p12 44779004 G/A 0.42 1.15 0.00184 0.084 0.798 0.041 0.080
2218080 5p12 44750087 C/T 0.43 1.15 0.00274 0.273 0.933 0.025 0.069
  1. aRs number, SNP identification (rs) number in dbSNP database; bMAF, minor allele frequency in the study population; cOR, estimated minor allele odds ratio under additive allelic effects model; dp.main, significance level for SNP association with breast cancer in additive allele effects model; eE-alone, P-value for dependence (interaction) of E-alone odds ratio on SNP from case-only analyses; fE+P and hCaD, corresponding interaction P-values for the other interventions; gDMQ, interaction P-value for DM among women with baseline percentage energy from fat in the upper quartile. Entries in bold are interaction effects significant at the nominal (0.05) level. WHI, Women's Health Initiative.